Millie
your market intelligence analyst
Search Results
160 results
Your search is now limited to «Hepatitis C» expert search.
ClinicalTrials.gov 07/23/2019 07:04
For all 3 groups the letter will be sent with the small Hepatitis C Scotland booklet "Hepatitis C treatments have changed.
More from ClinicalTrials.gov:
Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C.
More from International Journal of COPD:
Healio News 07/17/2019 13:42
Harvoni joins other direct-acting antivirals in demonstrating safety and high efficacy in younger pediatric patients with chronic hepatitis C, specifically those aged 3 years to younger than 6 years, according to results published in Hepatology.
More from Healio News:
Human medicines European public assessment report (EPAR): Maviret, glecaprevir / pibrentasvir, Hepatitis C, Chronic, Date of authorisation: 26/07/2017, Revision: 6, Status: Authorised.
More from European Medicines Agency - EMEA (EU):
FeedNavigator (EU) 07/16/2019 08:29
HCV has been recognized as the cause of chronic hepatitis C (CHC) since 1990.
More from FeedNavigator (EU):
Research has highlighted limited HCV knowledge among HCV patients ( 12 ) and the particular need for new and more accessible delivery of HCV educational information and support to marginalized individuals living with HCV ( 13.
More from Journal of Mobile Technology in Medicine:
Life Beyond Hepatitis C 07/15/2019 02:00
When we’re up against challenges and difficult situations in our lives, it’s important to remember how God has worked in our lives, and even more important to know He is still at work. We see this important example from David in the Bible when He was up against the giant Goliath. King Saul …
More from Life Beyond Hepatitis C:
PubMed News (NIH) 07/10/2019
Previous investigations failed to consistently detect IFN_ mRNA in HCV-infected livers, suggesting that pDCs may be incapable of producing IFN.
More from PubMed News (NIH):
Annals of Oncology 07/01/2019 20:00
Introduction: Various immune responses, including the activation of immune checkpoints and expression of chemokines and chemokine receptors, have been reported to promote hepatocellular carcinoma (HCC) progression. The aim of this study was to assess the differential expression of CCR5, Tim-3 and PD-1 by peripheral blood T and B lymphocytes from hepatitis C (HCV) patients with HCC and the impact of their pretreatment levels on treatment outcomes.
More from Annals of Oncology:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications